Observational studyCNS neuroscience & therapeutics2026
Association of Sleep Duration With Intracranial Atherosclerosis and Cerebral Small Vessel Disease: A Mediation by Metabolic Factors.
Observational study in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03178448 (PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)
Who cites it
1 citing paper in PubMed.
- Association of Sleep Duration With Intracranial Atherosclerosis and Cerebral Small Vessel Disease: A Mediation by Metabolic Factors.CNS neuroscience & therapeutics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsThis study aimed to explore the relationship between sleep duration and intracranial atherosclerosis and cerebral small vessel disease (CSVD), and pinpoint the potential mediating factors.
methodsData were derived from the cross-sectional baseline survey of the PRECISE (Poly-vascular Evaluation for Cognitive Impairment and Vascular Events) study. Participants were divided into short sleep (< 7 h), normal sleep (7-9 h), and long sleep (> 9 h) groups. The associations of sleep duration with intracranial atherosclerotic plaque, intracranial atherosclerotic burden, total CSVD score, and CSVD imaging markers were evaluated.
resultsWe enrolled 3038 participants (53.5% women; mean age: 61.2 ± 6.7 years). A long sleep duration was correlated with a higher risk of intracranial atherosclerotic plaque (long vs. normal: odds ratio [OR], 1.40 [95% CI, 1.10-1.78]), intracranial atherosclerotic burden (long vs. normal: common OR, 1.38 [95% CI, 1.09-1.75]), enlarged perivascular space in the basal ganglia (BG-EPVS) (long vs. normal: OR, 1.45 [95% CI, 1.07-1.97]); a short sleep duration indicated a rise in lacune (short vs. normal: OR, 1.67 [95% CI, 1.06-2.63]) after adjustment for covariates. The association of a long sleep duration with intracranial atherosclerotic plaque, intracranial atherosclerotic burden, and BG-EPVS (mediation percentage: 35.4%, 34.0%, 20.3%, respectively) was partially mediated by metabolic factors of blood pressure and fasting plasma glucose.
conclusionAberrant sleep duration may increase the potential risk for intracranial atherosclerosis and CSVD, which can be partially mediated by blood pressure and fasting plasma glucose. These findings highlight the benefits of clinical management of metabolic factors for those with aberrant sleep duration to prevent intracranial atherosclerosis and CSVD.
trial registrationNCT03178448.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.